The Role of Probiotic LH76 in Human Gut Health
Launched by WECARE PROBIOTICS CO., LTD. · Mar 8, 2025
Trial Information
Current as of April 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a probiotic called LH76 to see how it affects gut health in healthy adults. Probiotics are live bacteria that can provide health benefits, especially for our digestive system. The study will compare the effects of LH76 with a placebo (a treatment that has no active ingredients) to see if it helps improve the balance of bacteria in the gut, strengthens the intestinal barrier, and supports the immune system. Participants will provide samples of blood, urine, and stool, and will take either the probiotic or the placebo daily for the duration of the study.
To be eligible for this trial, participants must be between the ages of 65 and 74, have good eyesight and hearing, and be willing to attend three follow-up visits. They should also feel comfortable taking the daily supplement as instructed. However, people with certain health conditions, like serious digestive diseases or neurological disorders, will not be able to participate. This study is not yet recruiting, but if you're interested in learning more, keep an eye out for updates!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Willing to undergo 3 follow-up visits during the intervention period Be willing to provide blood, urine and stool samples 2 times during the intervention period
- • 2. Willing to self-administer probiotic or placebo once a day during the intervention period
- • 3. Good eyesight, can read and write, can wear glasses
- • 4. Have good hearing and be able to hear and understand all instructions during the intervention
- Exclusion Criteria:
- • 1. Digestive diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease)
- • 2. Have a serious neurological condition (epilepsy, stroke, severe head trauma, meningitis in the last 10 years, brain surgery, brain tumor, prolonged coma - not including general anaesthesia)
- • 3. Have received/are receiving treatment for the following mental disorders: alcohol/drug/substance abuse dependence, schizophrenia, psychosis, bipolar disorder
- • 4. Take medication for depression or low mood Internal organ failure (heart, liver or kidney failure, etc.)
- • 5. Have received radiation or chemotherapy in the past
- • 6. Have undergone a general anesthesia procedure/procedure within the past three years, or plan to undergo a general anesthesia procedure/procedure within the next 3 months during this trial period
- • 7. Have had hepatitis (hepatitis B, hepatitis C), HIV or syphilis in the past Open Contacts/Locations
About Wecare Probiotics Co., Ltd.
wecare probiotics co., ltd. is a leading biotechnology firm dedicated to advancing gut health through innovative probiotic solutions. With a robust portfolio of research and development initiatives, the company focuses on formulating high-quality probiotic products that are backed by scientific evidence. Committed to enhancing the well-being of individuals, wecare probiotics collaborates with healthcare professionals and academic institutions to conduct clinical trials that evaluate the efficacy and safety of its formulations. The company's mission is to empower consumers with effective, research-driven probiotic options, fostering a healthier future for all.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported